ReviewFrontiers in research metrics and analytics2025
The intellectual base and research fronts of LGR5: a bibliometric analysis.
Review in Frontiers in research metrics and analytics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is involved in canonical Wnt/β-catenin signaling and is a marker of stem cells in several tissues. It plays an important role in self-renewal, metastasis, and chemoresistance of tumors. The plasticity and potential of LGR5 (+) cancer stem cells could provide therapeutic targets for cancer. However, the data in this field is very limited and requires further investigation. Methods: This study aimed to explore the status and evolutionary trends of LGR5 research using bibliometric analysis. In total, 2,187 publications were retrieved from the Web of Science Core Collection. The period covered by the articles was from 1999 to 2023. CiteSpace, VOSviewer, R software, and Bibliometric Online Analysis Platform were used for bibliometric analysis and visualization. Results: The USA was the most productive country, with the highest centrality and largest single-country publications. The Netherlands was the earliest country to conduct LGR5 research. Cleavers, H from the Hubrecht Institute (KNAW) of the Netherlands was the most influential author as measured by H, G, and M-index values and contributions to the number of publications and citations. Intestinal stem cells were a hot topic, while keywords "LGR5 (+) stem cells," "inflammation," and "tumor microenvironment" exhibited the strongest burst in recent years, indicating a significant research focus in the future. Additionally, targeting LGR5 (+) stem cells in a specific phase of cancer and in combination with tumor microenvironment (TME) combination could be a future hotspot. Conclusion: Research on LGR5 continues to develop through active global efforts. This study offers a comprehensive analysis of LGR5 using bibliometric and visual methods, highlighting current research hotspots and potential directions for researchers interested in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.